{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T13:42:07Z","timestamp":1780926127159,"version":"3.54.1"},"reference-count":32,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.m2023.0035","type":"journal-article","created":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T07:58:37Z","timestamp":1681891117000},"source":"Crossref","is-referenced-by-count":3,"title":["Diffuse large B-cell lymphoma and related entities\u2014diagnosis, treatment, and follow-up"],"prefix":"10.3238","author":[{"given":"Moritz","family":"Ernst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"D\u00fchrsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Hellwig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Skoetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Borchmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2023,4,28]]},"reference":[{"key":"10.3238\/arztebl.m2023.0035_ref1","unstructured":"SEER: Surveillance, Epidemiology, and End Results (SEER) Program SEER*Stat Database. National Cancer Institute, DCCPS, Surveillance Research Program 2018."},{"key":"10.3238\/arztebl.m2023.0035_ref2","doi-asserted-by":"crossref","unstructured":"Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS: Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood 2006; 107: 265–76.","DOI":"10.1182\/blood-2005-06-2508"},{"key":"10.3238\/arztebl.m2023.0035_ref3","doi-asserted-by":"crossref","unstructured":"Coiffier B, Thieblemont C, Van Den Neste E, et al.: Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d‘Etudes des Lymphomes de l‘Adulte. Blood 2010; 116: 2040–5.","DOI":"10.1182\/blood-2010-03-276246"},{"key":"10.3238\/arztebl.m2023.0035_ref4","doi-asserted-by":"crossref","unstructured":"Cunningham D, Hawkes EA, Jack A, et al.: Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. Lancet 2013; 381: 1817–26.","DOI":"10.1016\/S0140-6736(13)60313-X"},{"key":"10.3238\/arztebl.m2023.0035_ref5","unstructured":"Alaggio R, Amador C, Anagnostopoulos I, et al.: The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 2022; 36: 1720–48."},{"key":"10.3238\/arztebl.m2023.0035_ref6","doi-asserted-by":"crossref","unstructured":"Metser U, Prica A, Hodgson DC, et al.: Effect of PET\/CT on the management and outcomes of participants with Hodgkin and aggressive Non-Hodgkin lymphoma: a multicenter registry. Radiology 2019; 290: 488–95.","DOI":"10.1148\/radiol.2018181519"},{"key":"10.3238\/arztebl.m2023.0035_ref7","unstructured":"D\u00fchrsen U, M\u00fcller S, Hertenstein B, et al.: Positron Emission Tomography-Guided Therapy of Aggressive Non-Hodgkin Lymphomas (PETAL): a multicenter, randomized phase III trial. J Clin Oncol 2018; 36: 2024–34."},{"key":"10.3238\/arztebl.m2023.0035_ref8","doi-asserted-by":"crossref","unstructured":"Freeman CL, Savage KJ, Villa DR, et al.: Long-term results of PET-guided radiation in patients with advanced-stage diffuse large B-cell lymphoma treated with R-CHOP. Blood 2021; 137: 929–38.","DOI":"10.1182\/blood.2020005846"},{"key":"10.3238\/arztebl.m2023.0035_ref9","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF): Diagnostik, Therapie und Nachsorge f\u00fcr Patient*innen mit einem diffusen gro\u00dfzelligen B-Zell-Lymphom und verwandten Entit\u00e4ten, Langversion 1.0, AWMF-Registernummer: 018\/038OL www.leitlinienprogramm-onkologie.de\/leitlinien\/dlbcl\/ (last accessed on 7 November 2022)."},{"key":"10.3238\/arztebl.m2023.0035_ref10","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF): Diagnostik, Therapie und Nachsorge f\u00fcr Patient*innen mit einem diffusen gro\u00dfzelligen B-Zell-Lymphom und verwandten Entit\u00e4ten, Leitlinienreport 1.0, AWMF-Registernummer: 018\/038OL. www.leitlinienprogramm-onkologie.de\/leitlinien\/dlbcl\/ (last accessed on 7 November 2022)."},{"key":"10.3238\/arztebl.m2023.0035_ref11","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF): Onkologische S3-Leitlinien – jetzt als App www.leitlinienprogramm-onkologie.de\/app\/ (last accessed on 7 November 2022)."},{"key":"10.3238\/arztebl.m2023.0035_ref12","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF): Onkologische Leitlinien. www.leitlinienprogramm-onkologie.de\/leitlinien\/ (last accessed on 7 November 2022)."},{"key":"10.3238\/arztebl.m2023.0035_ref13","unstructured":"Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e. V. (AWMF): AWMF online. Das Portal der wissenschaftlichen Medizin. www.awmf.org\/ (last accessed on 7 November 2022)."},{"key":"10.3238\/arztebl.m2023.0035_ref14","doi-asserted-by":"crossref","unstructured":"R\u00e9cher C, Coiffier B, Haioun C, et al.: Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03–2B): an open-label randomised phase 3 trial. Lancet 2011; 378: 1858–67.","DOI":"10.1016\/S0140-6736(11)61040-4"},{"key":"10.3238\/arztebl.m2023.0035_ref15","doi-asserted-by":"crossref","unstructured":"Pfreundschuh M, Tr\u00fcmper L, Osterborg A, et al.: CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379–91.","DOI":"10.1016\/S1470-2045(06)70664-7"},{"key":"10.3238\/arztebl.m2023.0035_ref16","doi-asserted-by":"crossref","unstructured":"Poeschel V, Held G, Ziepert M, et al.: Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. Lancet 2019; 394: 2271–81.","DOI":"10.1016\/S0140-6736(19)33008-9"},{"key":"10.3238\/arztebl.m2023.0035_ref17","doi-asserted-by":"crossref","unstructured":"Frontzek F, Ziepert M, Nickelsen M, et al.: Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial. Lancet Haematol 2021; 8: e267–e77.","DOI":"10.1016\/S2352-3026(21)00022-3"},{"key":"10.3238\/arztebl.m2023.0035_ref18","doi-asserted-by":"crossref","unstructured":"W\u00e4sterlid T, Hartman L, Sz\u00e9kely E, Jerkeman M: Impact on survival of addition of etoposide to primary chemotherapy in diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study. Hematol Oncol 2017; 35: 151–7.","DOI":"10.1002\/hon.2256"},{"key":"10.3238\/arztebl.m2023.0035_ref19","doi-asserted-by":"crossref","unstructured":"Gang AO, Str\u00f8m C, Pedersen M, et al.: R-CHOEP-14 improves overall survival in young high-risk patients with diffuse large B-cell lymphoma compared with R-CHOP-14. A population-based investigation from the Danish Lymphoma Group. Ann Oncol 2012; 23: 147–53.","DOI":"10.1093\/annonc\/mdr058"},{"key":"10.3238\/arztebl.m2023.0035_ref20","doi-asserted-by":"crossref","unstructured":"Tilly H, Morschhauser F, Sehn LH, et al.: Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med 2022; 386: 351–63.","DOI":"10.1056\/NEJMoa2115304"},{"key":"10.3238\/arztebl.m2023.0035_ref21","doi-asserted-by":"crossref","unstructured":"G\u00f3mez Le\u00f3n N, Vega G, Rodr\u00edguez-Vigil Junco B, Suevos Ballesteros C: Evaluation of diffuse large B-cell lymphoma patients with 64-slice multidetector computed tomography versus (18)FDG positron emission tomography\/computed tomography in initial staging and restaging after treatment. Medicina Clinica 2018; 151: 255–64.","DOI":"10.1016\/j.medcle.2018.08.003"},{"key":"10.3238\/arztebl.m2023.0035_ref22","doi-asserted-by":"crossref","unstructured":"Habermann TM, Weller EA, Morrison VA, et al.: Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 3121–7.","DOI":"10.1200\/JCO.2005.05.1003"},{"key":"10.3238\/arztebl.m2023.0035_ref23","doi-asserted-by":"crossref","unstructured":"Pfreundschuh M, Schubert J, Ziepert M, et al.: Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008; 9: 105–16.","DOI":"10.1016\/S1470-2045(08)70002-0"},{"key":"10.3238\/arztebl.m2023.0035_ref24","doi-asserted-by":"crossref","unstructured":"Oberic L, Peyrade F, Puyade M, et al.: Subcutaneous Rituximab-MiniCHOP compared with subcutaneous Rituximab-MiniCHOP plus lenalidomide in diffuse large B-cell lymphoma for patients age 80 years or older. J Clin Oncol 2021; 39: 1203–13.","DOI":"10.1200\/JCO.20.02666"},{"key":"10.3238\/arztebl.m2023.0035_ref25","doi-asserted-by":"crossref","unstructured":"Storti S, Spina M, Pesce EA, et al.: Rituximab plus bendamustine as front-line treatment in frail elderly (> 70 years) patients with diffuse large B-cell non-Hodgkin lymphoma: a phase II multicenter study of the Fondazione Italiana Linfomi. Haematologica 2018; 103: 1345–50.","DOI":"10.3324\/haematol.2017.186569"},{"key":"10.3238\/arztebl.m2023.0035_ref26","doi-asserted-by":"crossref","unstructured":"Weidmann E, Neumann A, Fauth F, et al.: Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas. Ann Oncol 2011; 22: 1839–44.","DOI":"10.1093\/annonc\/mdq671"},{"key":"10.3238\/arztebl.m2023.0035_ref27","doi-asserted-by":"crossref","unstructured":"Berro M, Arbelbide JA, Rivas MM, et al.: Hematopoietic cell transplantation-specific comorbidity index predicts morbidity and mortality in autologous stem cell transplantation. Biol Blood Marrow Transplant 2017; 23: 1646–50.","DOI":"10.1016\/j.bbmt.2017.06.014"},{"key":"10.3238\/arztebl.m2023.0035_ref28","doi-asserted-by":"crossref","unstructured":"Locke FL, Miklos DB, Jacobson CA, et al.: Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med 2022; 386: 640–54.","DOI":"10.1056\/NEJMoa2116133"},{"key":"10.3238\/arztebl.m2023.0035_ref29","doi-asserted-by":"crossref","unstructured":"Kamdar M, Solomon SR, Arnason J, et al.: Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet 2022; 399: 2294–308.","DOI":"10.1016\/S0140-6736(22)00662-6"},{"key":"10.3238\/arztebl.m2023.0035_ref30","doi-asserted-by":"crossref","unstructured":"Philip T, Guglielmi C, Hagenbeek A, et al.: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin‘s lymphoma. N Engl J Med 1995; 333: 1540–5.","DOI":"10.1056\/NEJM199512073332305"},{"key":"10.3238\/arztebl.m2023.0035_ref31","doi-asserted-by":"crossref","unstructured":"Sehn LH, Hertzberg M, Opat S, et al.: Polatuzumab vedotin plus bendamustine and rituximab in relapsed\/refractory DLBCL: survival update and new extension cohort data. Blood Advances 2022; 6: 533–43.","DOI":"10.1182\/bloodadvances.2021005794"},{"key":"10.3238\/arztebl.m2023.0035_ref32","doi-asserted-by":"crossref","unstructured":"Duell J, Maddocks KJ, Gonz\u00e1lez-Barca E, et al.: Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. Haematologica 2021; 106: 2417–26.","DOI":"10.3324\/haematol.2020.275958"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2023.0035","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T07:59:37Z","timestamp":1681891177000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2023.0035"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,28]]},"references-count":32,"URL":"https:\/\/doi.org\/10.3238\/arztebl.m2023.0035","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,28]]}}}